Drug intelligence / Profile preview

SP2H

Development stage: Preclinical
Lead developer: Sulis Therapeutics
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
Administration: Subcutaneous

Overview

SP2H is a potent and highly selective targeted STING (Stimulator of Interferon Genes) degrader developed by Sulis Therapeutics. It is designed to deplete STING in the liver and other peripheral organs, thereby reducing pathological STING activation, inflammation, and fibrosis. In preclinical models, SP2H has demonstrated efficacy in reducing NAFLD Activity Score (NAS) and liver fibrosis in mouse models of metabolic dysfunction-associated steatohepatitis (MASH), as well as improving survival and reducing inflammatory cytokines in Trex1-/- mouse models of systemic lupus erythematosus (SLE) and systemic sclerosis (SSc).

Targets

STING (Stimulator of interferon genes protein)

Beyond the preview

Go deeper on SP2H.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SP2H.